Clinical Phase Ii | List of Frontiers open access articles

Perspective

Published on 13 Aug 2021

From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product

in Translational Medicine

Sebastian Haeusner
Laura Herbst
Patrick Bittorf
Thomas Schwarz
Chris Henze
Marc Mauermann
Jelena Ochs
Robert Schmitt
Ulrich Blache
Anke Wixmerten

Frontiers in Medicine

doi 10.3389/fmed.2021.712917

6,057 views
13 citations

Review

Published on 25 Dec 2013

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

in Pharmacology of Anti-Cancer Drugs

Jan Stenvang
Iben Kümler
Sune Boris Nygård
David Hersey Smith
Dorte Nielsen
Nils Brünner
Jose Manuel Afonso Moreira

Frontiers in Oncology

doi 10.3389/fonc.2013.00313

15,228 views
43 citations

Systematic Review

Published on 05 Jan 2023

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

in Cancer Molecular Targets and Therapeutics

Peizhuo Yao
Yinbin Zhang
Shuqun Zhang
Xinyu Wei
Yanbin Liu
Chong Du
Mingyou Hu
Cong Feng
Jia Li
Fang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2022.1039882

9,732 views
16 citations

Review

Published on 03 Sep 2020

The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer

in Inflammation Pharmacology

Matthias Piesche
Jessica Roos
Benjamin Kühn
Jasmin Fettel
Nadine Hellmuth
Camilla Brat
Isabelle V. Maucher
Omar Awad
Carmela Matrone
Simon Gabriel Comerma Steffensen

Frontiers in Pharmacology

doi 10.3389/fphar.2020.01297

31,195 views
44 citations

Review

Published on 06 Jan 2026

Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances

in Pharmacology of Anti-Cancer Drugs

Mingyu Han
Zhaokai Zhou
Bi Qian
Yuanqi Zhang
Cheng Peng
Fu Peng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1714696

1,052 views

Review

Published on 15 Apr 2015

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial

in NK and Innate Lymphoid Cell Biology

Hanno M. Specht
Norbert Ahrens
Christiane Blankenstein
Thomas Duell
Rainer Fietkau
Udo S. Gaipl
Christine Günther
Sophie Gunther
Gregor Habl
Hubert Hautmann

Frontiers in Immunology

doi 10.3389/fimmu.2015.00162

19,301 views
98 citations

Original Research

Published on 02 Feb 2022

Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine

in Pharmacology of Anti-Cancer Drugs

Bing-Heng Yang
Wei-Zhi Lin
Yu-Ting Chiang
Yeu-Chin Chen
Chi-Hsiang Chung
Wu-Chien Chien
Chia-Yang Shiau

Frontiers in Oncology

doi 10.3389/fonc.2022.809014

3,514 views
4 citations

Articles

From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer

Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial

Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine